Cargando…
β-Lactam Therapeutic Drug Monitoring in Critically Ill Patients: Weighing the Challenges and Opportunities to Assess Clinical Value
OBJECTIVE: β-lactams are the cornerstone of empiric and targeted antibiotic therapy for critically ill patients. Recently, there have been calls to use β-lactam therapeutic drug monitoring (TDM) within 24–48 hours after the initiation of therapy in critically ill patients. In this article, we review...
Autores principales: | Dilworth, Thomas J., Schulz, Lucas T., Micek, Scott T., Kollef, Marin H., Rose, Warren E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259115/ https://www.ncbi.nlm.nih.gov/pubmed/35815181 http://dx.doi.org/10.1097/CCE.0000000000000726 |
Ejemplares similares
-
Weighing trees with lasers: advances, challenges and opportunities
por: Disney, M. I., et al.
Publicado: (2018) -
Pathogen-Negative Sepsis—An Opportunity for Antimicrobial Stewardship
por: Lockhart, Gabriel C, et al.
Publicado: (2019) -
2586. Comparison of Antimicrobial Regimens for Critically Ill Patients with Suspected or Confirmed Hospital-Acquired or Ventilator-Associated Pneumonia: A Retrospective, Cohort Study
por: Kosharek, Abigail, et al.
Publicado: (2023) -
The Current Status and Future Perspectives of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients
por: Novy, Emmanuel, et al.
Publicado: (2023) -
Eliminating viral hepatitis in the COVID-19 era: weighing challenge and opportunity
por: The Lancet Gastroenterology & Hepatology
Publicado: (2020)